Vantage Consulting Group Inc
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 9, 2025), Vantage Consulting Group Inc reported 4 stock positions worth $5.0 million. Its top holding was Cibus (CBUS) at 42.6% of the portfolio, followed by Babcock & Wilcox Enterpr (BW, 32.3%) and Adc Therapeutics (ADCT, 23.9%). Compared with Q4 2024, it sold out of 1. The biggest sale was an exit from Potbelly (PBPB).
- Most Recent 13F
- Q4 2025
- Location
- VIRGINIA BEACH, VA
- CIK
- 0001843547
- Portfolio Value
- $5.0M (Q1 2025)
- SEC Filing
- 0001843547-25-000007 ↗ filed May 9, 2025
Holdings Value
Holdings 4 stocks · $5.0M
| CBUS Cibus Inc. | 42.58% | 1,143,949 | $2.1M | No change |
| BW Babcock & Wilcox Enterpr | 32.34% | 2,416,200 | $1.6M | No change |
| ADCT Adc Therapeutics SA | 23.88% | 850,737 | $1.2M | No change |
| FIBROGEN INC | 1.21% | 195,707 | $61K | No change |
Portfolio Sells Q4 2024 → Q1 2025
| PBPB Potbelly Corp. | Sold out | 0.00% | −14.80 |
Portfolio Buys Q4 2024 → Q1 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q4 2025 | 3 | $19.7M | BW, ADCT, CBUS |
| Q3 2025 | 3 | $11.2M | BW, ADCT, CBUS |
| Q2 2025 | 3 | $5.7M | BW, ADCT, CBUS |
| Q1 2025 | 4 | $5.0M | CBUS, BW, ADCT, FIBROGEN INC |
| Q4 2024 | 5 | $10.5M | BW, CBUS, ADCT, PBPB, FIBROGEN INC |
| Q3 2024 | 4 | $11.4M | BW, CBUS, ADCT, FIBROGEN INC |
| Q2 2024 | 191 | $134.6M | SYNTAX STRATIFIED LARGE CAP, CBUS, SMDY, BW, SSLY |
| Q1 2024 | 212 | $157.3M | SYNTAX STRATIFIED LARGE CAP, CBUS, SMDY, ADCT, SSLY |